Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer

• Published in: Frontiers in immunology Vol. 13; p. 901772
• Main Authors: Zhang, Yuedi, Cui, Qiulin, Xu, Manman, Liu, Duo, Yao, Shuzhong, Chen, Ming
• Format: Journal Article
• Language: English
• Published: Frontiers Media S.A 27.06.2022
• Subjects: cold tumor; Immunology; immunotherapy; programmed death ligand 1 (PD-L1); programmed death-1 (PD-1); recurrent ovarian cancer
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2022.901772

Immunotherapies have revolutionized the treatment of a variety of cancers. Epithelial ovarian cancer is the most lethal gynecologic malignancy, and the rate of advanced tumor progression or recurrence is as high as 80%. Current salvage strategies for patients with recurrent ovarian cancer are rarely curative. Recurrent ovarian cancer is a “cold tumor”, predominantly due to a lack of tumor antigens and an immunosuppressive tumor microenvironment. In trials testing programmed death-1 (PD-1)/programmed death ligand 1 (PD-L1) blockade as a monotherapy, the response rate was only 8.0-22.2%. In this review, we illustrate the status of cold tumors in ovarian cancer and summarize the existing clinical trials investigating PD-1/PD-L1 blockade in recurrent ovarian cancer. Increasing numbers of immunotherapy combination trials have been set up to improve the response rate of EOC. The current preclinical and clinical development of immunotherapy combination therapy to convert an immune cold tumor into a hot tumor and their underlying mechanisms are also reviewed. The combination of anti-PD-1/PD-L1 with other immunomodulatory drugs or therapies, such as chemotherapy, antiangiogenic therapies, poly (ADP-ribose) polymerase inhibitors, adoptive cell therapy, and oncolytic therapy, could be beneficial. Further efforts are merited to transfer these results to a broader clinical application.